Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban vs VKA in Rheumatic Heart Disease with Atrial Fibrillation
NCT02832544Phase 3Completed
- Sponsor
- Population Health Research Institute
- Start
- Aug 2016
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 25
01
Overview
A Phase 3 trial of rivaroxaban in rheumatic heart disease (RHD), Atrial fibrillation (AFib), sponsored by Population Health Research Institute. Started Aug 2016; status: completed.
02
Drugs
rivaroxaban
03
Conditions
rheumatic heart disease (RHD)Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT02832544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02832544.